Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
According to the data, it has the following pharmacokinetics: Time to max concentration: 8-72 hours Max availability: 80% Half life: 5 days Time to steady state: No details provided With weekly dosing, the graph for Tirzepatide is shown below
As a triple incretin receptor agonist, it: Activates GLP-1 receptors , reducing appetite, slowing gastric emptying, and improving insulin secretion Activates GIP receptors , enhancing insulin response and potentially supporting fat metabolism Activates glucagon receptors , increasing energy expenditure and hepatic glucose output Whilst glucagon receptor activation increases hepatic glucose output, the net glycaemic effect of retatrutide is mitigated by the concurrent GLP-1 and GIP activity, resulting in overall improvements in glycaemic control in trial participants
These represent the highest weight loss outcomes recorded for any pharmacological compound in a Phase 2 clinical trial to date, exceeding both semaglutide and tirzepatide outcomes at equivalent treatment durations
Pregnancy and breastfeeding Insufficient research exists on copper peptide safety during pregnancy and breastfeeding
Expression of transcription factors involved in epithelial differentiation and marker genes of epithelial subpopulations indicated reduced terminal differentiation of epithelial cells under inflammatory conditions ( Figure 2A,B )
